| Literature DB >> 31499412 |
J G Grab1, D Skubleny2, N M Kneteman3.
Abstract
INTRODUCTION: A primary acinar cell carcinoma (ACC) of the liver was incidentally diagnosed in a clinically asymptomatic 80-year-old man. This study aimed to delineate critical diagnostic characteristics of an ACC originating uniquely from the liver to improve its future identification. PRESENTATION OF CASE: Enhanced MRI revealed a heterogenous, cystic 7.7 × 11.1 × 10.4 cm tumour occupying hepatic segments II and III. The mass demonstrated mild diffuse enhancement in hepatic arterial phase with minimal portal venous washout in a liver without cirrhotic features. A central stellate T2-hyperintense necrotic scar and outer capsule were apparent. No primary lesion or metastasis outside the liver was discernable. Post-left hepatic lobectomy, the tumour immunophenotype was atypical for presumptive diagnoses of hepatocellular carcinoma (HCC) or cholangiocarcinoma. Extensive morphologic workup on electron microscopy definitively diagnosed primary hepatic ACC by establishing presence of secretory zymogen-like granules, intracytoplasmic microvilli and acinar cell differentiation. Cytopathology revealed cellular lumen expressing PAS-positive diastase-resistant granular cytoplasmic contents. DISCUSSION: This case showcased the novel utility of electron microscopy that was crucial in yielding the definitive diagnosis. The previous literature on hepatic ACC was compiled here in context of the present case. The mechanism of hepatic acinar cell localization was also discussed.Entities:
Keywords: Acinar cell carcinoma; Cytopathology; Electron microscopy; Hepatobiliary surgery; Imaging
Year: 2019 PMID: 31499412 PMCID: PMC6734173 DOI: 10.1016/j.ijscr.2019.08.006
Source DB: PubMed Journal: Int J Surg Case Rep ISSN: 2210-2612
Fig. 1Primary hepatic ACC focal to segments 2 and 3. T1-weighted images shown as A, while T2-weighted images shown in B. The mass shows mild hypointensity, mild T2-weighted hyperintensity and restricted diffusion. Within it, a central stellate area of T1-weighted hypointensity and T2-weighted hyperintensity is visible. The internal central "scar" does not enhance. Within the mass, some radiating enhancing septae are visible. There is no fat nor lipid hyperexpression within the mass. The mass does exhibit mild diffuse enhancement in hepatic arterial phase (A – pre contrast; C – 0.5 min post contrast; D – 1 min post contrast) with slight portal venous phase washout and, on delayed imaging, a capsule (E – 5 min post contrast).
Fig. 2Positron emission tomography (PET) scan status 10 months post left hepatic lobectomy. No evidence of FDG avid local or distant metastatic disease was apparent.
Case presentations, defining characteristics, differential diagnoses, as well as outcome of the current study and five previous case reports of hepatic acinar cell carcinoma.
| Study | Age (Years) | Gender | Presentation | Comorbid Disease | Laboratory Tests | Defining Characteristics | DDX on Imaging | Definitive Diagnosis | Treatment | Follow-Up Post Diagnosis |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Study | 80 | M | Asymptomatic | Multiple (See Case Study Report) | Within normal limits | 7.7 × 11.1 × 10.4 cm Mass Heterogenous, Septated, Central Scar, Encapsulated, Hypoenhancement (Enhanced MRI) | Fibrolamellar HCC Cholangiocarcinoma | Pathology | Formal Resection | No Disease at 10 Months |
| Laino et al (2018) | 48 | M | Obstructive Jaundice | None Reported | Obstructive Biliary Pattern | 14 × 15 cm Mass Heterogenous, Cystic, Septated, Encapsulated, Delayed Enhancement, No Capsule (Enhanced CT) | Fibrolamellar HCC Cholangiocarcinoma Angiosarcoma Epithelioid Hemangioma Hepatoblastoma Distant Metastases | Pathology | Palliative Chemotherapy (Xeloda/ Oxaliplatin) | No Disease at 13 Months |
| Jordan et al (2017) | 54 | F | None | None Reported | Transaminitis, AFP of 82 IU/mL | Two Masses: 12.9 × 10.4 × 14.2 cm and 3.0 × 2.8 cm Hypoenhancment (Enhanced MRI) | Not Disclosed | Pathology | Formal Resection, Smaller Mass Unresectable Palliative Chemotherapy (FOLFOX) | Shrinking Local-Regional Disease at 20 Months |
| Wildgruber et al (2013) | 31 | M | Abdominal Pain | None Reported | Within normal limits | Heterogenous, Central Scar, Strong Arterial Blush (Enhanced MRI and CT) | Fibrolamellar HCC Hemangioendothelioma Angiosarcoma Cholangiocarcinoma | Pathology | Palliative Chemotherapy (Not Reported) | Died at 18 Months |
| Agaimy et al (2011) | 68 | F | Non-Specific Symptoms | None Reported | Within Normal Limits | 7–19 cm (mean of 12 cm) Heterogenous, Cystic, Septated, Encapsulated, Central Necrotic Scar, Focal Hemorrhage (Unenhanced CT) | Fibrolamellar HCC Cholangiocarcinoma | Pathology | Formal Resection | No Disease at 38 Months |
| 71 | M | Formal Resection | Died at 3 Months | |||||||
| 72 | M | Formal Resection Recurrence with Chemotherapy | Local Recurrent Disease at 22 Months | |||||||
| 49 | F | Formal Resection | No Disease at 28 Months | |||||||
| Hervieu et al (2008) | 35 | F | Abdominal Pain, Constitutional Symptoms | Hepatitis B | AFP of 6000 IU/mL | 5 × 5 cm Well limited, No Capsule, Hypervascular (Unenhanced CT) | Fibrolamellar HCC | Pathology | Formal Resection | No Disease at 7 Years |
Fig. 3Diastase-digested periodic acid-Schiff (PAS) stain shows intracellular PAS-positive granules consistent with secretory granules. Focally, microacinar structures (white asterisks) are visible. Original magnification x400.
Fig. 4Tumour with anastomosing acinar and trabecular growth pattern. Hematoxylin-eosin, original magnification x200.
Immunostaining selectivity of five previous primary hepatic acinar cell carcinoma (ACC).
| Primary Hepatic ACC Literature | ||||||
|---|---|---|---|---|---|---|
| Tumour Marker | Current Study | Laino et al (2018) | Jordan et al (2017) | Wildgruber et al. (2013) | Agaimy et al. (2011) | Hervieu et al. (2008) |
| LMW keratin | + | |||||
| CK7 | + | – | + | |||
| CK18 | + | |||||
| CK19 | – | + | – | |||
| CK20 | – | – | – | |||
| CD10 | – | – | ||||
| CD31 | – | |||||
| CD45 | – | |||||
| CD56 (N-CAM) | – | – | ||||
| CDX2 | – | |||||
| Synaptophysin | – | + | + | + | ||
| Chromogranin A | – | + | + | + | ||
| HepPar-1 | – | – | – | + | ||
| AFP | – | – | + | |||
| MOC31 | + | |||||
| GATA3 | – | |||||
| DOG1 | – | |||||
| TTF1 | – | – | ||||
| S-100 | – | |||||
| HMB45 | – | |||||
| MIB-1 | + (15%) | + (2-10%) | + (5-15%) | |||
| Trypsin | + | + | + | + | ||
| Chymotrypsin | + | + | ||||
| Amylase | – | + | ||||
| Lipase | – | + | ||||
| ER | – | |||||
| PR | – | |||||
| KL-1 | + | |||||
| Polyclonal CEA | – | |||||
| α1-AT | + | |||||
| E-Cadherin | + | |||||
| β-Catenin | + | |||||
Fig. 5Electron micrograph showing intracytoplasmic microvilli as well as intracytoplasmic membrane-bound vesicles (asterisk) consistent with secretory zymogen granules. Direct magnification x2500.